JPRN-UMIN000023956
Recruiting
未知
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed intermediate rhabdomyosarcoma. - Phase II study of VAC2.2/VI therapy for patients with newly diagnosed intermediate rhabdomyosarcoma.
Japan Rhabdomyosarcoma Study Group0 sites40 target enrollmentOctober 1, 2016
Conditionsrhabdomyosarcoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- rhabdomyosarcoma
- Sponsor
- Japan Rhabdomyosarcoma Study Group
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) patients with synchronous or metachronous concomitant malignancies 2\) patients with Charcot\-Marie\-Tooth disease or varicella 3\) patients with uncontrollable complications Interstitial pneumonia, pulmonary fibrosis, severe emphysema Uncontrollable diabetes mellitus Uncontrollable hypertension Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris) Liver failure, cirrhosis Renal failure 4\) patients with contraindication of drugs used in this study 5\) Female patients who are pregnant or breastfeeding mother or patients considering pregnancy 6\) Patients with any other inappropriate condition judged by physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000017004Japan Rhabdomyosarcoma Study Group18
Recruiting
Phase 2
Phase II study of VAC1.2/VI therapy for patients with newly diagnosed low-risk subset B rhabdomyosarcoma.rhabdomyosarcomaD012208JPRN-jRCTs051180200Miyachi Mitsuru18
Recruiting
Phase 2
Phase II study of VAC2.2/VI therapy for patients with newly diagnosed intermediate rhabdomyosarcomaJPRN-jRCTs051180207Hosono Ako40
Recruiting
Phase 2
Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcomarhabdomyosarcomaJPRN-UMIN000020891Japan Rhabdomyosarcoma Study Group22
Recruiting
Phase 2
Phase II study of VAC1.2/VA therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma.JPRN-jRCTs051180206Tsuchiya Kunihiko22